Reuse current reviewed evidence across formulation, dissolution, bioequivalence and Module 3 without silently copying values or manufacturing regulatory conclusions.
Boundary: This workspace creates internal, traceable drafts for qualified review. It does not approve a method, qualify a model, issue an electronic signature, publish an eCTD sequence or file an ANDA.
Build a proposed dissolution-development target from Q1/Q2 and QTPP/CQA evidence. Product-specific method development remains controlling.
Extract structured study-design defaults from current PSG, RLD and BE-strategy evidence. Missing product-specific constraints are not guessed.
Assemble section-level evidence links only from current eligible formulation, dissolution, BE, scale-up and quality records.
{}